Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) have been given a consensus rating of “Buy” by the seven research firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $26.00.

A number of research firms have weighed in on SRRK. Piper Sandler reaffirmed an “overweight” rating and set a $28.00 price objective on shares of Scholar Rock in a report on Tuesday, March 26th. BMO Capital Markets lifted their price objective on Scholar Rock from $29.00 to $31.00 and gave the company an “outperform” rating in a report on Thursday. Raymond James began coverage on Scholar Rock in a research report on Thursday, March 28th. They set a “strong-buy” rating and a $30.00 price target on the stock. Truist Financial restated a “buy” rating and set a $20.00 price target on shares of Scholar Rock in a research report on Wednesday, April 3rd. Finally, Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Scholar Rock in a research report on Tuesday, May 7th.

Scholar Rock Trading Up 0.2 %

Shares of SRRK opened at $9.45 on Tuesday. Scholar Rock has a 12-month low of $5.93 and a 12-month high of $21.17. The company has a quick ratio of 6.58, a current ratio of 6.58 and a debt-to-equity ratio of 0.24. The firm has a market capitalization of $753.64 million, a price-to-earnings ratio of -4.52 and a beta of 0.80. The stock’s 50-day moving average price is $12.59 and its 200 day moving average price is $14.94.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.11). During the same quarter in the previous year, the company posted ($0.46) earnings per share. As a group, research analysts predict that Scholar Rock will post -2.4 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Walleye Trading LLC acquired a new position in shares of Scholar Rock in the 1st quarter valued at $178,000. Jane Street Group LLC lifted its stake in shares of Scholar Rock by 95.5% in the 1st quarter. Jane Street Group LLC now owns 244,318 shares of the company’s stock valued at $4,339,000 after purchasing an additional 119,363 shares during the period. Kennedy Capital Management LLC acquired a new position in shares of Scholar Rock in the 1st quarter valued at $4,900,000. Bayesian Capital Management LP acquired a new position in shares of Scholar Rock in the 1st quarter valued at $258,000. Finally, Redmile Group LLC lifted its stake in shares of Scholar Rock by 0.3% in the 1st quarter. Redmile Group LLC now owns 6,419,610 shares of the company’s stock valued at $114,012,000 after purchasing an additional 17,105 shares during the period. 91.08% of the stock is currently owned by institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.